In conclusion, TGFβ1 treatment in myotubes increased glucose uptake, suggesting that short term increased serum TGFβ1 or localised TGFβ signalling dysfunction are unlikely to induce insulin resistance via defects in insulin signalling in the skeletal muscle. The gene discussed is TGFB1; the disease is Insulin resistance.